TAVR has changed the landscape for high-risk patients in need of new aortic heart valves. Now, research shows it also has lasting effects.
Shantell M. Kirkendoll
Shantell M. Kirkendoll is the senior communication representative for the University of Michigan Health System. She leverages social media and media relations to tell compelling stories about research and health care. She was a Knight Journalism Fellow at the Centers for Disease Control and Prevention and joined the University of Michigan Health System in 2009. Prior to that she was a print journalist for 20 years.